Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital disclosure notice rather than a financial results report.
Material Changes
The filing details the company's issued share capital as of September 28, 2012:
- Total Issued Ordinary Shares: 5,444,258,948 (25p each)
- Treasury Shares: 499,065,427
- Total Voting Rights: 4,945,193,521
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory capital disclosure.
Investor Verification Points
- Verify the total number of voting rights (4,945,193,521) for compliance with disclosure thresholds under Financial Services Authority rules.
- Confirm the number of shares held in Treasury (499,065,427) when calculating diluted share counts.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.